On Jan. 22, 2026, Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corporation (SRRK 3.20%), directly sold 14,898 shares in open-market transactions, totaling approximately $695,937, as disclosed in a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 14,898 |
| Transaction value | $695,938 |
| Post-transaction shares (direct) | 85,660 |
| Post-transaction value (direct ownership) | $4.1 million |
Transaction value based on SEC Form 4 weighted average purchase price ($46.71). Post-transaction value based on Jan. 22, 2026 closing price
Key questions
- What portion of Qatanani’s ownership capacity remains after this transaction?
Following this sale, direct ownership stands at 85,660 shares, or just 21% of total holdings. - Were any derivative securities or indirect entities involved in this transaction?
No, the sale was exclusively comprised of directly held common stock, with no activity involving restricted stock units, options, or trust/LLC entities, as confirmed by the SEC Form 4 and footnotes.
Company overview
| Metric | Value |
|---|---|
| *Price | $44.34 |
| Market capitalization | $4.52 billion |
| Net income (TTM) | -$353.43 million |
| *1-year price change | 4.18% |
*Price and 1-year price change calculated using Jan. 31, 2026 as the reference date.
Company snapshot
Scholar Rock Holding Corporation is a clinical-stage biotechnology company leveraging its expertise in protein growth factor signaling to develop therapies for severe diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and anemia.
What this transaction means for investors
The shares sold on January 22nd were part of a Rule 10b5-1 trading plan, which allows insiders to schedule sales in advance. So the sale wasn’t a voluntarily action conducted that day. And on the 16th and 14th, Qatanani sold more shares, but the shares sold on the 16th were to cover tax withholding obligations, and the ones sold two days earlier were also a part of a 10b5-1 plan.
Scholar Rock has big plans for 2026, as it plans on launching one of its key product candidates, apitegromab, into U.S. and European markets, following approval from the Food and Drug Administration and other global agencies. The company claims that apitegromab is the world’s first and only muscle-targeted treatment candidate to improve motor function in patients with spinal muscular atrophy (SMA), a severe and genetic neuromuscular disease.
The company is still operating with a net loss, and the stock increased by barely 2% in 2025, but if its apitegromab project is successful, SRRK has a stronger case as a promising investment.
